Literature DB >> 24003233

Endogenous interleukin-1β in neuropathic rats enhances glutamate release from the primary afferents in the spinal dorsal horn through coupling with presynaptic N-methyl-D-aspartic acid receptors.

Xisheng Yan1, Han-Rong Weng.   

Abstract

Excessive activation of glutamate receptors and overproduction of proinflammatory cytokines, including interleukin-1β (IL-1β) in the spinal dorsal horn, are key mechanisms underlying the development and maintenance of neuropathic pain. In this study, we investigated the mechanisms by which endogenous IL-1β alters glutamatergic synaptic transmission in the spinal dorsal horn in rats with neuropathic pain induced by ligation of the L5 spinal nerve. We demonstrated that endogenous IL-1β in neuropathic rats enhances glutamate release from the primary afferent terminals and non-NMDA glutamate receptor activities in postsynaptic neurons in the spinal dorsal horn. Myeloid differentiation primary response protein 88 (MyD88) is a mediator used by IL-1β to enhance non-NMDA glutamate receptor activities in postsynaptic neurons in the spinal dorsal horn. Presynaptic NMDA receptors are effector receptors used by the endogenous IL-1β to enhance glutamate release from the primary afferents in neuropathic rats. This is further supported by the fact that NMDA currents recorded from small neurons in the dorsal root ganglion of normal rats are potentiated by exogenous IL-1β. Furthermore, we provided evidence that functional coupling between IL-1β receptors and presynaptic NMDA receptors at the primary afferent terminals is mediated by the neutral sphingomyelinase/ceramide signaling pathway. Hence, functional coupling between IL-1β receptors and presynaptic NMDA receptors at the primary afferent terminals is a crucial mechanism leading to enhanced glutamate release and activation of non-NMDA receptors in the spinal dorsal horn neurons in neuropathic pain conditions. Interruption of such functional coupling could be an effective approach for the treatment of neuropathic pain.

Entities:  

Keywords:  Cell Signaling; Glia; Glutamate Receptors Ionotropic (AMPA, NMDA); Pain; Patch Clamp

Mesh:

Substances:

Year:  2013        PMID: 24003233      PMCID: PMC3798525          DOI: 10.1074/jbc.M113.495465

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  81 in total

1.  Modulation of transmitter release by presynaptic resting potential and background calcium levels.

Authors:  Gautam B Awatramani; Gareth D Price; Laurence O Trussell
Journal:  Neuron       Date:  2005-10-06       Impact factor: 17.173

2.  Presynaptic effects of NMDA in cerebellar Purkinje cells and interneurons.

Authors:  M Glitsch; A Marty
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

3.  Presynaptic mechanism for long-term potentiation in the hippocampus.

Authors:  J M Bekkers; C F Stevens
Journal:  Nature       Date:  1990-08-23       Impact factor: 49.962

4.  Transmitter timecourse in the synaptic cleft: its role in central synaptic function.

Authors:  J D Clements
Journal:  Trends Neurosci       Date:  1996-05       Impact factor: 13.837

5.  Intraplantar-injected ceramide in rats induces hyperalgesia through an NF-κB- and p38 kinase-dependent cyclooxygenase 2/prostaglandin E2 pathway.

Authors:  Tim Doyle; Zhoumou Chen; Carolina Muscoli; Lina M Obeid; Daniela Salvemini
Journal:  FASEB J       Date:  2011-05-06       Impact factor: 5.191

Review 6.  The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia.

Authors:  Joseph H Neale; Rafal T Olszewski; Laura M Gehl; Barbara Wroblewska; Tomasz Bzdega
Journal:  Trends Pharmacol Sci       Date:  2005-09       Impact factor: 14.819

7.  Blind patch-clamp recordings from substantia gelatinosa neurons in adult rat spinal cord slices: pharmacological properties of synaptic currents.

Authors:  M Yoshimura; S Nishi
Journal:  Neuroscience       Date:  1993-03       Impact factor: 3.590

8.  Peptidoglycan induces cyclooxygenase-2 expression in macrophages by activating the neutral sphingomyelinase-ceramide pathway.

Authors:  Bing-Chang Chen; Huey-Mei Chang; Ming-Jen Hsu; Chwen-Ming Shih; Yi-Hua Chiu; Wen-Ta Chiu; Chien-Huang Lin
Journal:  J Biol Chem       Date:  2009-06-15       Impact factor: 5.157

9.  Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain.

Authors:  Wei Guo; Hu Wang; Mineo Watanabe; Kohei Shimizu; Shiping Zou; Stacey C LaGraize; Feng Wei; Ronald Dubner; Ke Ren
Journal:  J Neurosci       Date:  2007-05-30       Impact factor: 6.167

10.  IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1 subunit in rats.

Authors:  Rui-Xin Zhang; Aihui Li; Bing Liu; Linbo Wang; Ke Ren; Haiqing Zhang; Brian M Berman; Lixing Lao
Journal:  Pain       Date:  2007-08-06       Impact factor: 7.926

View more
  44 in total

1.  Spinal inhibition of p38 MAP kinase reduces inflammatory and neuropathic pain in male but not female mice: Sex-dependent microglial signaling in the spinal cord.

Authors:  Sarah Taves; Temugin Berta; Da-Lu Liu; Sophie Gan; Gang Chen; Yong Ho Kim; Thomas Van de Ven; Stefan Laufer; Ru-Rong Ji
Journal:  Brain Behav Immun       Date:  2015-10-19       Impact factor: 7.217

2.  Nerve injury-induced epigenetic silencing of opioid receptors controlled by DNMT3a in primary afferent neurons.

Authors:  Linlin Sun; Jian-Yuan Zhao; Xiyao Gu; Lingli Liang; Shaogen Wu; Kai Mo; Jian Feng; Weixiang Guo; Jun Zhang; Alex Bekker; Xinyu Zhao; Eric J Nestler; Yuan-Xiang Tao
Journal:  Pain       Date:  2017-06       Impact factor: 6.961

Review 3.  Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain.

Authors:  Gang Chen; Yu-Qiu Zhang; Yawar J Qadri; Charles N Serhan; Ru-Rong Ji
Journal:  Neuron       Date:  2018-12-19       Impact factor: 17.173

4.  Macrophage repolarization with targeted alginate nanoparticles containing IL-10 plasmid DNA for the treatment of experimental arthritis.

Authors:  Shardool Jain; Thanh-Huyen Tran; Mansoor Amiji
Journal:  Biomaterials       Date:  2015-05-19       Impact factor: 12.479

Review 5.  Microglial Modulation as a Target for Chronic Pain: From the Bench to the Bedside and Back.

Authors:  Elena S Haight; Thomas E Forman; Stephanie A Cordonnier; Michelle L James; Vivianne L Tawfik
Journal:  Anesth Analg       Date:  2019-04       Impact factor: 5.108

6.  Chronic pain and impaired glial glutamate transporter function in lupus-prone mice are ameliorated by blocking macrophage colony-stimulating factor-1 receptors.

Authors:  Xisheng Yan; Dylan W Maixner; Fen Li; Han-Rong Weng
Journal:  J Neurochem       Date:  2017-02-01       Impact factor: 5.372

7.  AMPKα1 knockout enhances nociceptive behaviors and spinal glutamatergic synaptic activities via production of reactive oxygen species in the spinal dorsal horn.

Authors:  Dylan W Maixner; Xisheng Yan; Shelley B Hooks; Han-Rong Weng
Journal:  Neuroscience       Date:  2016-04-04       Impact factor: 3.590

8.  Ropivacaine and Bupivacaine prevent increased pain sensitivity without altering neuroimmune activation following repeated social defeat stress.

Authors:  Caroline M Sawicki; January K Kim; Michael D Weber; Brant L Jarrett; Jonathan P Godbout; John F Sheridan; Michelle Humeidan
Journal:  Brain Behav Immun       Date:  2017-11-08       Impact factor: 7.217

Review 9.  Activity-triggered tetrapartite neuron-glial interactions following peripheral injury.

Authors:  Ke Ren; Ronald Dubner
Journal:  Curr Opin Pharmacol       Date:  2015-09-30       Impact factor: 5.547

Review 10.  Pathological pain and the neuroimmune interface.

Authors:  Peter M Grace; Mark R Hutchinson; Steven F Maier; Linda R Watkins
Journal:  Nat Rev Immunol       Date:  2014-02-28       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.